Abstract:Acute myeloid leukemia (AML) is a kind of heterogeneous hematologic malignancy with high incidence, which is usually treated by intensive and maintenance treatment with large dose of conventional chemotherapy drugs. However, cell resistance is still an unsolved problem. The abnormal expression of miRNAs is closely related to the pathogenesis and progression of AML, and affects the drug resistance of cancer cells. miR-149-3p plays an important role in the resistance of cancer cells to cisplatin, and plays an excellent anti-tumor activity. By studying the function of miR-149-3p, it is expected to find new therapeutic methods to reverse chemotherapy resistance. In order to explore the mechanism of action of miR-149-3p on AML chemotherapeutic drug sensitivity, we explored the relationship between the Warburg effect and AML chemotherapeutic drug resistance. Based on AML cells, transfection of miR-149-3p inhibitor/NC and Warburg effect inhibitor (2DG) and PI3K/AKT pathway inhibitor (LY294002) were used to investigate the mechanism of IFN-γ regulating chemotherapy resistance of AML cells through Warburg effect. Down-regulation of miR-149-3p significantly inhibited drug sensitivity of AML cells. Down-regulation of miR-149-3p significantly promoted proliferation and invasion of AML cells while inhibiting apoptosis by up-regulating the expression of Bcl-2 and down-regulating the expression of Bax. Down-regulation of miR-149-3p significantly promoted the expression of Warburg effect-related proteins hexokinase 2 (HK2), lactate dehydrogenase A (LDHA), and Glucose transporter 1 (GLUT1), glucose consumption, lactic acid, and intracellular ATP production. After inhibiting the Warburg effect with 2DG, the effect of miR-149-3p was inhibited, suggesting that upregulation of miR-149-3p reversed AML cell resistance by inhibiting the Warburg effect. In addition, miR-149-3p interacted with AKT1. Down-regulation of miR-149-3p increased the expression of inosine phosphate 3 kinase (PI3K), protein kinase B (AKT), and multi-drug resistance protein (MDR1). LY294002 inhibited the expression of these proteins, and down-regulation of miR-149-3p reversed the effect of LY294002 and improved the drug resistance of cells. Upregulation of miR-149-3p expression may potentially be a therapeutic target for AML resistance. It has been shown to inhibit PI3K/AKT pathway activation, thereby inhibiting the Warburg effect, and affecting cell proliferation, apoptosis, and drug resistance.

[Correlation of miR-155 Expression with Drug Sensitivity of FLT3-ITD+ Acute Myeloid Leukemia Cell Line and Its Mechanism]

Profiling of Micrornas in Aml Cells Following Overexpression or Silencing of the Vegf Gene

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted Mir-150 Nanoparticles.

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway

[Targeting Mir155 Restores Chemotherapy Sensitivity in Drug-Resistant Myeloma Cell-Line RPMI8226/DOX Cells].

MiR-425 Expression Profiling in Acute Myeloid Leukemia Might Guide the Treatment Choice Between Allogeneic Transplantation and Chemotherapy

miR-149-3p Enhances Drug Sensitivity of AML Cells by Inhibiting Warburg Effect Through PI3K/AKT Pathway

High Expression of Mir-363 Predicts Poor Prognosis and Guides Treatment Selection in Acute Myeloid Leukemia

High Expression of Mir-25 Predicts Favorable Chemotherapy Outcome in Patients with Acute Myeloid Leukemia.

MicroRNA 217 Inhibits Cell Proliferation and Enhances Chemosensitivity to Doxorubicin in Acute Myeloid Leukemia by Targeting KRAS

Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis

[Expression of miR-155 in Acute Myeloid Leukemia and Its Clinical Significance].

The Knockdown of MAGI2-AS3 Inhibits Drug Resistance in Acute Myeloid Leukemia by Up Regulating Mir-155

MicroRNA-181b-5p insufficiency predicts treatment response failure risk and unfavorable event-free survival as well as overall survival in acute myeloid leukemia patients

Mir-181B Increases Drug Sensitivity in Acute Myeloid Leukemia Via Targeting HMGB1 and Mcl-1.

Low Expression Of Microrna-340 Confers Adverse Clinical Outcome In Patients With Acute Myeloid Leukemia

[The Role and Mechanism of MiR-451 in Multidrug Resistance of Leukemia Cell Line K562/A02]

Repression Of Mir-495, A Microrna Associated With Favorable Outcome Of Acute Myeloid Leukemia Patients, Is Required For The Mll-Associated Leukemogenesis

[MiR-217 Targeting PI3K/Akt Pathway Enhances Sensitivity of Adriamycin to Acute Myeloid Leukemia]

High expression of miR‐338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy